Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.
Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.
The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.
Timely initiation of DAA treatment, regardless of insurance type, is crucial in reducing HCV-related death, disparity, and transmission, concluded CDC researchers.
A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.
Clinical research into treatments for NASH is hampered by the need for invasive biopsies but a new blood test using 2 biomarkers could be a game changer, say study authors.
An overview of recommendations from the American Association of Clinical Endocrinology for the management of NAFLD in adults.
Get an overview of the recent AACE guidelines for diagnosing NAFLD in adults in primary care settings.
Results of the prespecified analysis from the REGENERATE trial confirm 2019 data demonstrating statistically significant improvement in fibrosis without worsening NASH.
The sodium-glucose cotransporter 1/2 inhibitor at 150 mg was associated with a significant 32% reduction in liver enzyme levels in a phase 2a clinical trial.